Literature DB >> 8274615

Emerging fungal pathogens in immunocompromised patients: classification, diagnosis, and management.

S E Vartivarian1, E J Anaissie, G P Bodey.   

Abstract

Fungi such as Fusarium species, Trichosporon species, Curvularia species, and Alternaria species previously were thought to represent contamination or harmless colonization when isolated from immunocompromised patients. More recently, the pathogenic role of these and other fungi has been clearly established. Three diverse groups of fungi are responsible for these emerging infections: the agents of phaeohyphomycosis and hyalohyphomycosis and certain yeasts. Reports of the emergence of these organisms as significant pathogens may be ascribed to increasing awareness by physicians and microbiologists, aggressive culture of patient specimens, increasingly cytotoxic chemotherapy, and selection of resistant organisms by the widespread empirical use of amphotericin B. Infections with these fungi tend to be disseminated and are frequently fatal in immunocompromised hosts. Treatment of these infections is not standardized. Experimental therapy in murine models of fungal infections suggests a role for newer agents, combination antifungal chemotherapy, and immunotherapy.

Entities:  

Mesh:

Year:  1993        PMID: 8274615     DOI: 10.1093/clinids/17.supplement_2.s487

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  40 in total

Review 1.  Developments in fungal taxonomy.

Authors:  J Guarro; A M Stchigel
Journal:  Clin Microbiol Rev       Date:  1999-07       Impact factor: 26.132

2.  In vitro activity of Syn-2869, a novel triazole agent, against emerging and less common mold pathogens.

Authors:  E M Johnson; A Szekely; D W Warnock
Journal:  Antimicrob Agents Chemother       Date:  1999-05       Impact factor: 5.191

3.  Relapsing cutaneous alternariosis in a kidney transplant recipient cured with liposomal amphotericin B.

Authors:  E Merino; J Bañuls; V Boix; A Franco; J Guijarro; J Portilla; I Betlloch
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2003-01-16       Impact factor: 3.267

4.  Preliminary evaluation of a semisolid agar antifungal susceptibility test for yeasts and molds.

Authors:  H Provine; S Hadley
Journal:  J Clin Microbiol       Date:  2000-02       Impact factor: 5.948

5.  Antifungal susceptibility and pathogenic potential of environmental isolated filamentous fungi compared with colonizing agents in immunocompromised patients.

Authors:  A B A Teixeira; M Silva; L Lyra; E A Luz; J Uno; H Takada; M Miyaji; K Nishimura; A Z Schreiber
Journal:  Mycopathologia       Date:  2005-09       Impact factor: 2.574

6.  Phaeohyphomycosis caused by Alternaria infectoria in a renal transplant recipient.

Authors:  T Halaby; H Boots; A Vermeulen; A van der Ven; H Beguin; H van Hooff; J Jacobs
Journal:  J Clin Microbiol       Date:  2001-05       Impact factor: 5.948

7.  Phaeohyphomycosis caused by Chaetomium globosum in an allogeneic bone marrow transplant recipient.

Authors:  A B A Teixeira; P Trabasso; M L Moretti-Branchini; F H Aoki; A C Vigorito; M Miyaji; Y Mikami; M Takada; A Z Schreiber
Journal:  Mycopathologia       Date:  2003       Impact factor: 2.574

8.  Aspergillus, Penicillium and Talaromyces isolated from house dust samples collected around the world.

Authors:  C M Visagie; Y Hirooka; J B Tanney; E Whitfield; K Mwange; M Meijer; A S Amend; K A Seifert; R A Samson
Journal:  Stud Mycol       Date:  2014-06       Impact factor: 16.097

9.  Rapid molecular diagnosis of posttraumatic keratitis and endophthalmitis caused by Alternaria infectoria.

Authors:  Consuelo Ferrer; Javier Montero; Jorge L Alió; José L Abad; José M Ruiz-Moreno; Francisca Colom
Journal:  J Clin Microbiol       Date:  2003-07       Impact factor: 5.948

10.  Antiproliferative, antifungal, and antibacterial activities of endophytic alternaria species from cupressaceae.

Authors:  Jalal Soltani; Mahdieh S Hosseyni Moghaddam
Journal:  Curr Microbiol       Date:  2014-05-07       Impact factor: 2.188

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.